A5031154868- Chronic Lymphocytic Leukemia Research
- Immunodeficiency and Autoimmune Disorders
- Pancreatic and Hepatic Oncology Research
- Epigenetics and DNA Methylation
- Cancer Genomics and Diagnostics
- PI3K/AKT/mTOR signaling in cancer
- Lymphoma Diagnosis and Treatment
Odense University Hospital
2022-2025
University of Southern Denmark
2024-2025
Patients with chronic lymphocytic leukemia (CLL) undergoing ibrutinib treatment often experience incomplete response, yet the molecular level underlying clonal inertia remains to be explored. We investigated and clinical dynamics of CLL during 16 months monotherapy by analyzing blood samples from two patients who continued having cells in peripheral treatment. At diagnosis, burden within B cell compartment was found 55% (pt1) 86% (pt2) for dominant clones. following these clones still...
Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of B cells due to constitutive B-cell receptor (BCR) signaling, leading apoptosis resistance and increased proliferation. This study evaluates effects Bruton Tyrosine Kinase (BTK) inhibitor ibrutinib on molecular composition, clonality, kinetics during treatment in CLL patients. Employing a multi-omics approach up 3.2 years follow-up, we analyzed data from 24 patients, specifically focusing nine patients treated with...
Background: Introduction of the orally administered tyrosine kinase inhibitor ibrutinib, a drug approved for relapsed or refractory mantle cell lymphoma in late 2013 and chronic lymphocytic leukemia 2014, has changed treatment algoritms B-cell malignancies improved progression-free survival. Ibrutinib irreversibly targets Bruton’s (BTK), thus interrupting receptor signaling. However, it is known that mutations BTK gene, located on X chromosome, can mediate acquired resistance, specifically...